Seroba invests in early-stage life sciences companies developing biotech therapeutics and medical devices. The firm describes its focus as value creation through backing innovations in biotech and medtech. It invests predominantly in Western Europe with selective exposure to North America. Fund IV targets up to 12 investments in total.
€123M (Seroba Fund IV, final close announced February 2024) AUM68/100 Power Score™- FoundedDublin, Ireland
Announced above-target final close of Seroba Fund IV at €123M in February 2024, with LPs including the European Investment Fund, Ireland Strategic Investment Fund, Enterprise Ireland, AIB and CDP Venture Capital.
2024
Portfolio company Fusion Pharmaceuticals (NASDAQ: FUSN) acquired by AstraZeneca for up to $2.4B; announced March 2024, completed June 2024.
2025
Portfolio company Azafaros raised a €132M Series B led by Jeito Capital and co-led by Forbion Growth, with Seroba participating.